Viral clearance capability of monoclonal antibody purification
Open Access
- 21 February 2024
- journal article
- research article
- Published by Elsevier in Biologicals
- Vol. 85, 101751
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- AstraZeneca Pharmaceuticals LP
This publication has 57 references indexed in Scilit:
- Using high throughput screening to define virus clearance by chromatography resinsBiotechnology and Bioengineering, 2013
- Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody productionBiotechnology Progress, 2010
- Analysis of viral clearance unit operations for monoclonal antibodiesBiotechnology and Bioengineering, 2010
- The Tissue-Type Plasminogen Activator StoryArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Removal of endogenous retrovirus‐like particles from CHO‐cell derived products using Q sepharose fast flow chromatographyBiotechnology Progress, 2009
- Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO‐cell derived biotherapeuticsBiotechnology and Bioengineering, 2009
- Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology productsBiotechnology and Bioengineering, 2008
- Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common ThemeCritical Reviews in Biochemistry and Molecular Biology, 2008
- Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformationNature, 2006
- The FDA Advisory Panel's Decision on rt‐PAThe Journal of Clinical Pharmacology, 1987